EHDEN

Electronic health data in a European network
EHDEN logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 12
Grant agreement number
806968

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
14 105 750
EFPIA in kind
14 811 607
Total Cost
28 917 357

Summary

Healthcare data has the potential to transform our understanding of health, disease and outcomes, yet it is currently scattered across multiple institutions and countries, stored in different formats, and subject to different rules. This makes it very difficult to fully utilise this data to benefit patients.  The goal of EHDEN is to make the large-scale analysis of health data in Europe a reality. The project aims to do this by building a federated data network of allowing access to the data of 100 million EU citizens standardised to a common data model. At the heart of the project will be a group of trained, certified small and medium-sized enterprises (SMEs) responsible for transforming the data owned by hospitals to the common data model. The data will remain under complete control of the original data owner, thereby ensuring ethical and local data privacy rules are respected.

EHDEN is part of IMI’s Big Data for Better Outcomes (BD4BO) programme.

Participants Show participants on map

EFPIA companies
  • Abbvie Inc, North Chicago, Illinois, United States
  • Astrazeneca AB, Södertälje, Sweden
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • Celgene Management SARL, Couvet, Switzerland
  • Institut De Recherches Internationales Servier, Suresnes, France
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France
  • UCB Biopharma SPRL, Brussels, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
  • National Institute For Health And Care Excellence, Manchester, United Kingdom
  • Stiftelsen WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden
  • Tartu Ulikool, Tartu, Estonia
  • Universidade De Aveiro, Aveiro, Portugal
  • University of Oxford, Oxford, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • International Consortium For Healthoutcomes Measurement LTD, London, United Kingdom
  • Odysseus Data Services Sro, Praha, Czech Republic
  • Synapse Research Management Partners SL, Barcelona, Spain
  • The Hyve BV, Utrecht, Netherlands
Patient organisations
  • European Patients’ Forum (EPF), Brussels, Belgium
Associated partners
  • Eli Lilly and Company Limited, Basingstoke, United Kingdom
  • Novartis Pharma AG, Basel, Switzerland
  • Pfizer Limited, Sandwich, Kent , United Kingdom

CONTACT

Project coordinator
Peter RIJNBEEK
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
p.rijnbeek[at]erasmusmc.nl